Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-06

Clinical Trial Update: Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of ravulizumab versus placebo in adults with dermatomyositis was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Dermatomyositis | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-12-06